1 active not recruiting, 1 recruiting, 1 terminated, 1 unknown. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Active not recruiting 1, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow molgramostim: new trials by email Literature Review of molgramostim trials Research Report on molgramostim
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). Molgramostim - Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 | Recruiting | Savara Inc. | 5 | 2025-10-22 | 2026-02-19 |
| Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Molgramostim, Placebo, Molgramostim Open-label - Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 | Active not recruiting | Savara Inc. | 164 | 2021-05-19 | 2026-11-18 |
| Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Molgramostim - Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 | Terminated | Savara Inc. | 60 | 2018-04-16 | 2024-07-03 |
| Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients CSF470 vaccine, BCG, Molgramostim, interferon alpha 2b - Cutaneous Melanoma | Phase 2 / Phase 3 | Unknown | Laboratorio Pablo Cassara S.R.L. | 108 | 2009-04-01 | 2015-09-02 |
Pulmonary Alveolar Proteinosis, Acquired (3) · Melanoma (1) · Pulmonary Alveolar Proteinosis (1)
Savara Inc. (3) · Laboratorio Pablo Cassara S.R.L. (1)
Germany (3) · France (2) · Greece (2) · Italy (2) · Netherlands (2) · Turkey (Türkiye) (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Belgium (1) · Canada (1) · Denmark (1) · Ireland (1) · Israel (1) · Japan (1)
Bruce Trapnell, MD (1) · Francesco Bonella, Prof. (1) · Matthias Griese, MD, (1)
PMID 28620382, PMID 29774030, PMID 40834301
2017 (1)